Join the club for FREE to access the whole archive and other member benefits.

Treatments that delay ageing could be worth trillions of dollars to the US alone

As more people live longer (lifespan) it is essential that their health keeps up too (healthspan)


Key points from article :

Life expectancy at birth increased from 32 years in 1900 to 73 by 2019.

In high-income countries, most improvements are in mortality rates after 70 years of age.

Chance reaching 90, has gone from a 1 in 100 long shot to a 1 in 3 probability.

This means more people are living to ages where their health is getting worse.

Disease burden has shifted from infectious diseases towards non-communicable diseases.

A health intervention that lowered mortality at every age, increasing life expectancy by one year, would be worth $37 trillion in the US.

The most valuable health priority of all is to ensure that healthspan rises to match lifespan.

It will require the development of treatments which target ageing itself.

Researchers have proven that age reversal is possible in mouse and human cells.

Treatments that delay ageing are highly beneficial because they lessen the probability of disease.

Research by Andrew J Scott (London Business School), Martin Ellison (University of Oxford) and David A. Sinclair (Harvard Medical School) published in Nature Aging.

Mentioned in this article:

Click on resource name for more details.

Andrew Scott

Professor of Economics at London Business School, Co-founder of The Longevity Forum

David Sinclair

Harvard professor. Author of Lifespan.

Martin Ellison

Professor of Economics, University of Oxford

Nature Aging

Journal spanning the entire spectrum of research into aging

Topics mentioned on this page:
Policy, Ageing Research